Feasibility of somatostatin receptor scintigraphy in the detection of occult primary gastro-entero-pancreatic (gep) neuroendocrine tumours

Nuclear Medicine Communications

Volumn 25, Issue 5, 2004, Pages 445-449

  Savelli, Giordano ^a   Lucignani, Giovanni ^b   Seregni, Ettore ^a   Marchianò, Alfonso ^a   Serafini, Gianluca ^a   Aliberti, Gianluca ^a   Villano, Carlo ^a   Maccauro, Marco ^a   Bombardieri, Emilio ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

Author keywords

Gastro entero pancreatic tumours; In pentetreotide scintigraphy; Neuroendocrine tumours; Primary of unknown origin; Prognostic value

Indexed keywords

ADULT; ARTICLE; CANCER DIAGNOSIS; CANCER SURGERY; CARCINOID SYNDROME; CLINICAL ARTICLE; CLINICAL EXAMINATION; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC APPROACH ROUTE; FEASIBILITY STUDY; FEMALE; FOLLOW UP; GASTROINTESTINAL TUMOR; HUMAN; LIVER METASTASIS; MALE; NEUROENDOCRINE TUMOR; OCCULT CANCER; PANCREAS TUMOR; SCINTIGRAPHY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SOMATOSTATIN RECEPTOR SCINTIGRAPHY; TREATMENT INDICATION; WHOLE BODY SCINTISCANNING;

DIGESTIVE SYSTEM NEOPLASMS; FEASIBILITY STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASMS, UNKNOWN PRIMARY; NEUROENDOCRINE TUMORS; RADIOPHARMACEUTICALS; RECEPTORS, SOMATOSTATIN; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; SOMATOSTATIN;

EID: 2342479090     PISSN: 01433636     EISSN: 14735628     Source Type: Journal    
DOI: 10.1097/00006231-200405000-00004     Document Type: Article

References (22)

1. Oberg K. Neuroendocrine gastrointestinal tumours. Ann Oncol 1996; 7:453-463.
2. Lamberts SWJ, Bakker WH, Reubi JC, Krenning EP. Somatostatin receptor imaging in the localization of endocrine tumours. N Engl J Med 1990; 323:1246-1249.
3. Seregni E, Chiti A, Bombardieri E. Radionuclide imaging of neuroendocrine tumours: biological basis and diagnostic results. Eur J Nucl Med 1998; 25:639-658.
4. Krenning EP, Kwekkeboom DJ, Bakker WH, Bremman WA, Kooij PP, Oei HY, et al. Somatostatin receptor scintigraphy with (111In-DTPA-D-Phe1)- and (123I-Try3)-octreotide: the Rotterdam experience with more than 1000 patients. Eur J Nucl Med 1993; 20:716-731.
5. Zeitels J, Naunheim K, Kaplan EL, Straus F 2nd. Carcinoid tumors: a 37-year experience. Arch Surg 1982; 117:732-737.
6. Fuster D, Navasa M, Pons F, Vidal-Sicart S, Mateos JJ, Lomena F, et al. In-111 octreotide scan in a case of a neuroendocrine tumor of unknown origin. Clin Nucl Med 1999; 24:955-958.
7. Kirshbom PM, Kherani AR, Onaitis MW, Feldman JM, Tyler DS. Carcinoids of unknown origin: comparative analysis with foregut, midgut, and hindgut carcinoids. Surgery 1998; 124:1063-1070.
8. Seregni E, Ferrari L, Stivanello M, Dogliotti L. Laboratory tests for neuroendocrine tumours. Q J Nucl Med 2000; 44:22-41.
9. Modlin IM, Sandor A. An analysis of 8305 cases of carcinoid tumours. Cancer 1997; 79:813-829.
10. Leonard JR, Nystrom J. Diagnostic evaluation of patients with carcinoma of unknown primary tumour site. Semin Oncol 1993; 3:244-250.
11. Chorost MI, McKinley B, Tschoi M, Glosh BC. The management of the unknown primary. J Am Coll Surg 2001; 193:666-677.
12. Bombardieri E, Maccauro M, de Deckere E, Savelli G, Chiti A. Nuclear medicine imaging of neuroendocrine tumours. Ann Oncol 2001; 12:S51-S61.
13. Bajetta E, Bichiaso E, Artale S, Celio L, Ferrari L, Di Bartolomeo M, et al. New clinical trials for the treatment of neuroendocrine tumors. Q J Nucl Med 2000; 44:96-101.
14. Chiti A, Fanti S, Savelli G, Romeo A, Bellanova B, Rodari M et al. Comparison of somatostatin receptor imaging, computed tomography and ultrasound in the clinical management of neuroendocrine gastro-entero-pancreatic tumours. Eur J Nucl Med 1998; 25:1396-1403.
15. Rindi G, Capella C, Solcia E. Introduction to a revised clinicopathological classification of neuroendocrine tumors of the gastroenteropancreatic tract. Q J Nucl Med 2000; 44 (1):13-21.
16. Di Bartolomeo M, Bajetta E, Buzzoni R, Mariani L, Carnaghi C, Somma L, et al. Clinical efficacy of octreotide in the treatment of metastatic neuroendocrine tumors. A study by the Italian Trials in Medical Oncology Group. Cancer 1996; 77:402-408.
17. Bajetta E, Carnaghi C, Somma L, Stampino CG. A pilot safety study of capecitabine, a new oral fluoropyrimidine, in patients with advanced neoplastic disease. Tumori 1996; 82:450-452.
18. Lebtahi R, Cadiot G, Sarda L, Daou D, Faraggi M, Petegnief Y, et al. Clinical impact of somatostatin receptor scintigraphy in the management of patients with neuroendocrine gastroenteropancreatic tumors. J Nucl Med 1997; 38:853-858.
19. Jensen RT. Peptide therapy. Recent advances in the use of somatostatin and other receptor antagonists. In: Lewis JH, Dubois A. (editors). Current Clinical Topics in Gastrointestinal Pharmacology. Malden, MA: Blackwell Science; 1977 pp. 144-223.
20. Lamberts SWJ, Reubi JC, Krenning EP. Somatostatin and the concept of peptide receptor scintigraphy in oncology. Semin Oncol 1994; 21:1-5.
21. Bakker WH, Krenning EP, Breman WA, Kooij PP, Reubi JC, Koper JW, et al. In vivo use of a radioiodinated somatostatin analogue: dynamics, metabolism, and binding to somatostatin receptor-positive tumors in man. J Nucl Med 1991; 32:1184-1189.
22. Godwin JD 2nd. Carcinoid tumors. An analysis of 2837 cases. Cancer 1975; 36:560-569.